Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Learn more about the gut microbiome’s digestion of the amino acid tryptophan, which creates byproducts with potential for ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

Shares of digital healthcare provider, Hims & Hers Heath (NYSE:HIMS) dropped post market, after it reported Q2 revenue below expectations, hurt by challenges in the compounding obesity drugs market.

While GLP‑1 receptor agonists may be best known for aiding weight loss and regulating digestion, gastroenterologists are also drawing attention to the therapies’ effect on the brain. Indeed, recent ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions like obesity and type 2 diabetes, many lacked insurance or a routine place for ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.